1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc.

NTII
Neurobiological Technologies, Inc.US flagOther OTC
0.00
USD
- -
- -
2,702.00Market Cap
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
TTM
Revenue per Share
0.44
2.14
0.09
- -
2.02
- -
0.77
0.94
0.82
3.03
4.07
0.76
0.98
1.07
Basic EPS, GAAP
-7.9
-2.22
-3.42
-1.9
0.67
-1.7
-1.04
-0.61
-6.59
-6.84
-3.26
-0.84
0.12
0.42
Free Cash Flow per Basic Share
-7.51
-2.45
-2.97
-1.96
0.57
-2.06
-1.21
-0.71
-2.65
2.13
-3.05
-1.07
-0.61
-0.41
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.44
1.67
-1.9
4.29
4.28
2.41
1.45
6.96
-17.75
-23.37
-25.18
-6.46
-4.55
-4.35
Tangible Book Value per Share
3.44
1.67
-1.9
4.14
4.19
2.36
1.43
6.92
1.52
-2.86
-5.15
1.03
0.87
1.07
Basic Weighted Avg Shares
1
1
1
2
2
3
3
3
4
4
4
19
27
27
Sales/Revenue/Turnover
- -
2
- -
- -
5
- -
2
3
3
12
18
15
26
29
Operating Margin (%)
-1,809.1
-108.22
-3,756.31
-327,573,000
21.57
- -
-142.97
-86.59
-405.76
-133.22
-88.28
-113.12
13.98
41.82
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-7
-2
-4
-3
2
-4
-3
-2
-25
-28
-14
-16
3
11
Effective Tax Rate (%)
- -
- -
- -
- -
2.57
- -
- -
- -
- -
- -
- -
- -
- -
1.75
Profit Margin (%)
-1,809.1
-103.49
-3,709.15
-311,473,200
33.22
- -
-135.7
-64.89
-805.86
-225.62
-79.94
-110.58
11.85
39.19
Working Capital
3
2
-1
8
10
5
4
20
5
12
-4
22
23
29
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
3
2
-1
8
11
7
4
21
6
-11
-22
20
24
29
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
16.68
- -
- -
- -
- -
- -
- -
- -
-2.52
-9.22
Return on Common Equity (%)
-107.49
-89.68
- -
- -
18.56
-52.86
-54.88
-14.88
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'09
Jun'09
Sep'10
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
18
18
24

Working Capital

FRC

•

in mil. unless spec.
Mar'09
Jun'09
Sep'10
Total Current Assets
22
25
30
Cash, Cash Equivalents & STI
22
24
26
Accounts Receivable, Net
- -
- -
3
Inventories
- -
- -
- -
Total Current Liabilities
12
1
1
Payables & Accruals
6
1
1
ST Debt
- -
- -
- -
Deferred Revenue
6
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-108.72%
-88.62%
16.07%
Free Cash Flow
-71.81%
-4.09%
-20.65%
Net Income, GAAP
53.51%
228.01%
-119.13%
Sales/Revenue/Turnover
- -
82.92%
78.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
4
4
4
4
15
2009
4
3
3
16
26
2010
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-0.19
-0.36
-0.19
- -
-0.84
2009
-0.1
-0.29
-0.02
- -
0.12
2010
0.2
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
John B. Stuppin
Full Time Employees
4
Sector
Healthcare
Industry
Biotechnology
Address
2000 Powell Street EmeryVille CA United States of America 94608
IPO Date
Oct 31, 1994
Similar Companies
Erasca, Inc. (ERAS)
Solid Biosciences Inc. (SLDB)
BeOne Medicines AG (ONC)
Tourmaline Bio, Inc. (TRML)
BioMarin Pharmaceutical Inc. (BM8.F)
InMed Pharmaceuticals Inc. (INM)
Business
Neurobiological Technologies, Inc. (NTII) operates under a plan of liquidation and dissolution approved by stockholders in October 2009, following the failure of its lead drug candidate ancrod (Viprinex) in a Phase III trial for ischemic stroke. The company, founded in 1987 and headquartered in Emeryville, California, previously focused on in-licensing and developing investigational biopharmaceuticals for neurological and neurodegenerative disorders, including memantine for neuropathic pain and dementia, which generated royalty payments after licensing to Merz Pharma and Forest Laboratories; corticotropin-releasing factor (Xerecept) for brain tumor edema, outlicensed to Celtic Pharma; dynorphin A for pain management; and ancrod, acquired via Empire Pharmaceuticals in 2004 for stroke treatment. It employed a virtual model outsourcing to contract organizations, targeting markets in the United States and Europe with no active subsidiaries or parent relationships post-dissolution.